trending Market Intelligence /marketintelligence/en/news-insights/trending/6l8i6NyNkYybVievn_PqBQ2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Cancer Genetics to acquire contract research company vivoPharm

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Cancer Genetics to acquire contract research company vivoPharm

Cancer Genetics Inc. agreed to acquire vivoPharm Pty. Ltd. for about $12 million.

VivoPharm is a contract research organization that provides preclinical oncology and immuno-oncology services, offering integrated service in different disease areas to the biotechnology and pharmaceutical industries.

The purchase price includes $1.2 million in cash, while the remaining 90% will be shares of Cancer Genetics based on the volume-weighted average price over the last 20 business days.

Cancer Genetics signed an equity financing arrangement for up to $16 million to fund the acquisition and increase working capital for general corporate purposes. The initial tranche of funding will be $3 million, while additional tranches can be accessed by Cancer Genetics at its discretion over the next 2 years.

Ralf Brandt, CEO and managing director of vivoPharm, will become president of discovery and early development services at Cancer Genetics upon completion of the acquisition.

Cancer Genetics expects the acquisition of vivoPharm to contribute about $5 million in annual revenue and expects it to be immediately accretive.

The deal, which has been approved by the boards of both companies, is expected to close Aug. 15.